Eli Lilly (NYSE: LLY ) unveiled a set of expectations for its 2013 results, and reconfirmed its guidance for last year in an official statement. For the current fiscal year, the company believes it will post revenue of $22.6 billion-$23.4 billion, and non-GAAP earnings of $3.75-$3.90 per share. That compares favorably to analyst expectations, which averaged $22.9 billion and $3.72, respectively.
For 2012, the company stood by its previous assumptions of $3.30-$3.40 EPS.
That year, Lilly lost patent protection for Zyprexa, an anti-psychotic treatment that was its best-selling drug of all time. In 2013 the same will happen for its current number one, the anti-depressant drug Cymbalta.
The firm is to announce its 4Q and full-year 2012 results on January 29.